![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1402026
¼¼°èÀÇ ÀÇ·á ¹Ì¿ë ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, ½Ã¼úº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®Medical Aesthetics Market Forecasts to 2030 - Global Analysis By Product, Procedure, Application, End User and by Geography |
Stratistics MRC¿¡ µû¸£¸é ¼¼°è ÀÇ·á ¹Ì¿ë ½ÃÀåÀº 2023³â 234¾ï 6,000¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È CAGR 14.2%·Î ¼ºÀåÇØ 2030³â 594¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÇ·á ¹Ì¿ëÀº ÃÖ¼Òħ½ÀÀû, ºñħ½ÀÀû ¹Ì¿ë ½Ã¼úÀ» ÅëÇØ ȯÀÚÀÇ ¿Ü¸ð¸¦ °³¼±ÇÏ´Â µ¥ ÁßÁ¡À» µÎ´Â ÀÇ·á ºÐ¾ßÀÔ´Ï´Ù. ÁÖ¸§, ÀÜÁÖ¸§, ÇǺΠóÁü, °úµµÇÑ Áö¹æ°ú °°Àº ¹®Á¦¸¦ Ä¡·áÇϱâ À§ÇØ ÀÌ·¯ÇÑ ½Ã¼úÀº ¾ó±¼°ú ½ÅüÀÇ ¿Ü¸ð¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ¶ÇÇÑ, º¸Å彺³ª ÇǺΠÇÊ·¯¿Í °°Àº ÁÖ»ç´Â ³ëÈÀÇ Â¡Èĸ¦ °¨¼Ò½Ã۰í, ÇǺΠȸÃá°ú Á¦¸ð¸¦ À§ÇÑ ·¹ÀÌÀú Ä¡·á, ºñ¼ö¼úÀû ½Åü À±°û ±â¼ú µîÀÌ ÀϹÝÀûÀÎ ÀÇ·á ¹Ì¿ë Ä¡·áÀÇ ¿¹ÀÔ´Ï´Ù.
2021³â 2¿ù¿¡ ¹ßÇ¥µÈ BAAPSÀÇ Á¶»ç¿¡ µû¸£¸é, 2021³â ¿µ±¹¿¡¼ 15,405°ÇÀÇ ¹Ì¿ë ¼ö¼úÀÌ ÀÌ·ç¾îÁ³´Ù°í ÇÕ´Ï´Ù. ¹Ì¿ë ½Ã¼úÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á¿ë ¹Ì¿ë ±â±âÀÇ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÇ·á¿ë ¹Ì¿ë Àåºñ¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
°í·ÉÈ ÁøÇà
ÀÇ·á¿ë ¹Ì¿ë±â±â ½ÃÀåÀº Àü ¼¼°è °í·ÉÈ Àα¸ÀÇ Áõ°¡°¡ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÁÖ¸§, ÀÜÁÖ¸§, ÇǺΠź·Â ÀúÇÏ´Â ³ªÀ̰¡ µé¾î°¨¿¡ µû¶ó ÀÚ¿¬½º·´°Ô ÁøÇàµÇ´Â ³ëÈ Çö»óÀÇ ÇÑ ¿¹ÀÔ´Ï´Ù. ¶ÇÇÑ, Àþ¾î º¸À̰íÀÚ ÇÏ´Â ¿å±¸¿Í ¹Ì¿ë ½Ã¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ³ëÈ¿Í °ü·ÃµÈ ¹Ì¿ë ¹®Á¦¿¡ ´ëÇÑ Ä¡·áµµ ³ôÀº ¼ö¿ä¸¦ º¸À̰í ÀÖ½À´Ï´Ù.
ºÒ·®ÇÑ »óȲ°ú ¹®Á¦ÀÇ À§Ç輺
ÀáÀçÀûÀΠȯÀÚµéÀº ÀÇ·á ¹× ¹Ì¿ë ½Ã¼ú·Î ÀÎÇÑ ºÎÀÛ¿ëÀ̳ª ÇÕº´ÁõÀÇ À§Çè ¶§¹®¿¡ ÁÖÀúÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÈÀü ±âÁØÀº ¸¹ÀÌ ¹ßÀüÇßÁö¸¸, ÇÕº´ÁõÀÇ ¹ß»ýÀº Çö½ÇÀûÀÌµç »ó»óÀûÀÌµç »çȸÀû ½Å·Ú¸¦ ÈѼÕÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Á¦¾àÀ» ¿ÏÈÇϱâ À§ÇØ ¾÷°è ÀÌÇØ °ü°èÀÚµéÀº °ø°³¼º, Æ÷°ýÀû ÀΠȯÀÚ ±³À° ¹× Áö¼ÓÀûÀÎ ¾ÈÀü ÇÁ·ÎÅäÄÝ °³¼±¿¡ ³ôÀº ¿ì¼± ¼øÀ§¸¦ µÎ¾î¾ßÇÕ´Ï´Ù.
Çõ½Å°ú ±â¼úÀÇ Áøº¸
Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú ±â¼ú ¹ßÀüÀº ÀÇ·á ¹Ì¿ë ½ÃÀå¿¡ Å« ±âȸ¸¦ °¡Á®´ÙÁÝ´Ï´Ù. ¸Ó½Å·¯´×(ML), Áõ°Çö½Ç(AR), ÀΰøÁö´É(AI)ÀÇ µµÀÔÀ¸·Î Ä¡·á °èȹ°ú ½Ã¹Ä·¹À̼ÇÀÌ ´õ¿í Á¤È®ÇÏ°í °³ÀÎ鵃 °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ¿¡³ÊÁö ±â¹Ý Ç÷§Æû°ú ÷´Ü ·¹ÀÌÀú¿Í °°Àº Çõ½ÅÀûÀÎ ÀåºñÀÇ °³¹ßÀº ÃÖ¼Òħ½ÀÀû, ºñħ½ÀÀû ½Ã¼úÀ» À§ÇÑ »õ·Î¿î ±æÀ» ¿¾îÁÙ °ÍÀÔ´Ï´Ù.
°æ±âħü¿Í °³ÀμҺñ °¨¼Ò
ÀÇ·á ¹× ¹Ì¿ë°ú °°Àº ºñÇʼöǰ ¼ºñ½º¿¡ ´ëÇÑ ¼ÒºñÀÚ ÁöÃâÀº °æ±â ħü, ºÒȲ, ¼¼°è ±ÝÀ¶À§±âÀÇ ¿µÇâÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. °¡Ã³ºÐ ¼ÒµæÀÇ º¯È¿¡ ¹Î°¨Çϱ⠶§¹®¿¡ ÀÌ »ê¾÷Àº °æ±â ħü ½Ã ¼ö¿ä °¨¼ÒÀÇ ¿µÇâÀ» ¹Þ±â ½±½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ À§ÇùÀ» ±Øº¹Çϱâ À§Çؼ´Â ºÒÅõ¸íÇÑ °æÁ¦ »óȲ¿¡¼ ȸº¹·ÂÀ» ³ôÀ̱â À§ÇÑ Àü·«À» ¼ö¸³ÇÏ°í ¸¶ÄÉÆÃ Á¢±Ù ¹æ½ÄÀ» ¼öÁ¤ÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.
ÀÇ·á¹Ì¿ë ½ÃÀåÀº COVID-19 »çÅ·ΠÀÎÇØ Å« Ÿ°ÝÀ» ÀÔ¾ú½À´Ï´Ù. ÆÒµ¥¹Í Ãʱ⿡´Â Á¤ºÎÀÇ ºÀ¼â, ¼±ÅÃÀû ½Ã¼ú Á¦ÇÑ, ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ȯÀÚ ¹æ¹®°ú ½Ã¼ú Ƚ¼ö°¡ Å©°Ô °¨¼ÒÇß½À´Ï´Ù. ¾÷°è´Â Áø·á¼Ò Æó¼â, °ø±Þ¸Á È¥¶õ, ±âº»ÀûÀÎ ÀÇ·á ¼ºñ½º¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ¿ì¼±¼øÀ§ º¯È µîÀ» °æÇèÇß½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí Á¦ÇÑÀÌ ¿ÏÈµÇ¸é¼ ¹Ì¿ë ¼ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Á¡Â÷ ȸº¹µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ Àü¿°º´Àº °¡»ó Áø·á¿Í ¿ø°Ý Áø·áÀÇ º¸±ÞÀ» °¡¼ÓÈÇÏ¿© ȯÀÚµé°úÀÇ ±³·ù¿¡ º¯È¸¦ °¡Á®¿Ô½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È °¡½¿¼ºÇü ºÐ¾ß°¡ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸Á
¹Ì¿ë ½ÃÀå¿¡¼ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÏ´Â ºÐ¾ß°¡ ¹Ù·Î °¡½¿¼ºÇüÀÔ´Ï´Ù. °¡½¿ ¼ºÇüÀº º¸Çü¹°À̳ª Áö¹æ À̽ÄÀ» ÅëÇØ °¡½¿ÀÇ Å©±â¿Í ¸ð¾çÀ» Ű¿ì´Â ¼ö¼ú °úÁ¤ÀÔ´Ï´Ù. À¯¹æ È®´ë ¼ö¼úÀÇ ¸Å·ÂÀº ¹Ì¿ë»óÀÇ ¹®Á¦¸¦ ¿ÏÈÇϰí Àڱ⠱àÁ¤°¨À» Çâ»ó½Ãų ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¶ÇÇÑ ¹Ì¿ë ¾÷°è¿¡¼ ÀÌ ¼ö¼úÀÇ Áö¼ÓÀûÀÎ Àαâ´Â ¹ÌÀû ±âÁØÀÇ ÁøÈ, ½Åü ±àÁ¤¼ºÀÇ Áõ°¡, ¼ö¼ú ±â¼úÀÇ Çâ»ó µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.
Ŭ¸®´Ð, º´¿ø, ¸ÞµðÄà ½ºÆÄ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»ó
ÀÇ·á ½ºÆÄ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÞµðÄà ½ºÆÄ´Â ÀüÅëÀûÀÎ ½ºÆÄÀÇ Æ¯Â¡°ú °øÀÎµÈ ÀÇ·á Àü¹®°¡°¡ °ü¸®ÇÏ´Â ÀÇ·á ¼ºñ½º¸¦ °áÇÕÇÏ¿© ºäƼ Äɾ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ºÆÄÀÇ ¸Å·ÂÀº °í°´¿¡°Ô È޽İú À£ºù ¼ºñ½º¿Í ÇÔ²² ÃÖ÷´Ü ¿¡½ºÅׯ½ Æ®¸®Æ®¸ÕÆ®¸¦ Á¦°øÇÏ¿© °í°´¿¡°Ô À¯ÀϹ«ÀÌÇÑ Á¾ÇÕÀûÀÎ °æÇèÀ» Á¦°øÇÑ´Ù´Â µ¥ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸ÞµðÄà ½ºÆÄ ¸ðµ¨Àº ½ºÆÄ °°Àº ȯ°æ¿¡¼ ºñħ½ÀÀû ½Ã¼úÀ» ¿øÇÏ´Â ´Ù¾çÇÑ °í°´µéÀ» ÀÚÁÖ ²ø¾îµéÀ̱⠶§¹®¿¡ ³ôÀº ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù.
¼¼°è ¿¡½ºÅׯ½ »ê¾÷¿¡¼ ºÏ¹Ì°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÈ÷ ¹Ì±¹¿¡¼´Â ´Ù¾çÇÑ ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ¸¹¾Æ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ Àß °®ÃçÁ® ÀÖ°í, ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ÀνÄÀÌ ³ôÀ¸¸ç, ¿Ü¸ð¿Í ¾Æ¸§´Ù¿ò¿¡ ´ëÇÑ °ü½ÉÀÌ ³ôÀº °ÍÀÌ ÀÌ Áö¿ªÀÇ ¹ø¿µÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ·¹ÀÌÀú Ä¡·á, ÇǺΠȸÃá, ½Åü À±°û ¼ºÇü, ¾ó±¼ ÁÖ»ç ¹× ±âŸ ½Ã¼úÀº ¸ðµÎ ºÏ¹Ì¿¡¼ Á¦°øµÇ´Â ´Ù¾çÇÑ ¹Ì¿ë ½Ã¼úÀÇ ÀϺÎÀÔ´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÏ¸ç ¼¼°è ¹Ì¿ë ½ÃÀå¿¡¼ ¿ªµ¿ÀûÀÎ ÈûÀ» ¹ßÈÖÇϰí ÀÖ½À´Ï´Ù. Áß»êÃþÀÇ Áõ°¡, ¾Æ¸§´Ù¿ò¿¡ ´ëÇÑ ±âÁØÀÇ º¯È, °¡Ã³ºÐ ¼ÒµæÀÇ Áõ°¡´Â ¸ðµÎ Áß±¹, ÀϺ», Çѱ¹ µîÀÇ ±¹°¡¿¡¼ ¹Ì¿ë ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀº ºñħ½ÀÀû ½Ã¼úÀÇ ºü¸¥ µµÀÔ°ú ¹Ì¿ë °È¿¡ ´ëÇÑ ¹®ÈÀû ¼ö¿ëÀ¸·Î ¾÷°èÀÇ ÃÖÀü¼±¿¡ ¼°í ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Medical Aesthetics Market is accounted for $23.46 billion in 2023 and is expected to reach $59.42 billion by 2030 growing at a CAGR of 14.2% during the forecast period. Medical aesthetics is a field of medicine that focuses on improving a patient's appearance using a range of minimally invasive and non-invasive cosmetic procedures. With the aim of treating issues like wrinkles, fine lines, sagging skin, and extra fat, these procedures aim to enhance the appearance of the face and body. Moreover, injectables like Botox and dermal fillers, which lessen signs of aging, laser therapy for skin rejuvenation and hair removal, and non-surgical body contouring techniques are examples of common medical aesthetic treatments.
According to the BAAPS survey released in February 2021, 15,405 cosmetic surgical procedures were performed in the United Kingdom in 2021. The increasing number of aesthetic procedures requires medical aesthetic devices. This is creating the need for medical aesthetic devices and driving the market's growth.
Increasingly aging population
The market for medical aesthetics is largely driven by the global increase in the aging population. Wrinkles, fine lines, and a decrease in skin elasticity are examples of the natural progression of signs of aging that occur as people age. Additionally, treatments for age-related cosmetic concerns are in high demand due to the desire to look youthful and the advancements in aesthetic procedures.
Hazard of unfavorable circumstances and issues
Potential patients may hesitate due to the inherent risk of unfavorable outcomes or complications from medical aesthetic procedures. Safety standards have come a long way, but incidents of complications-real or imagined-can undermine public confidence. Furthermore, in order to alleviate this constraint, industry stakeholders need to place a high priority on openness, comprehensive patient education, and ongoing safety protocol improvement.
Innovation and technological advancements
Continuous innovations and advancements in technology offer the medical aesthetics market a sizable opportunity. Treatment planning and simulations are made more accurate and individualized by incorporating machine learning (ML), augmented reality (AR), and artificial intelligence (AI). Additionally, new paths for minimally invasive and non-invasive procedures are opened by the development of innovative devices like energy-based platforms and sophisticated lasers.
Economic downturns and declines in consumer spending
Consumer expenditure on non-essential services, such as medical aesthetics, can be impacted by economic downturns, recessions, or global financial crises. Due to its sensitivity to changes in disposable income, the industry is susceptible to a decline in demand during recessions. Moreover, to navigate this threat, it is imperative to develop resilience strategies and modify marketing approaches during periods of economic uncertainty.
The market for medical aesthetics has been significantly impacted by the COVID-19 pandemic. Early in the pandemic, there was a marked decline in patient visits and procedural volumes due to government-imposed lockdowns, limitations on elective procedures, and increased safety concerns. The industry experienced clinic closures, supply chain disruptions, and changes in consumer priorities toward basic healthcare. Pent-up demand for aesthetic services drove a gradual recovery, nevertheless, as restrictions eased. Additionally, the pandemic hastened the uptake of virtual consultations and telemedicine, which has altered patient interactions.
The Breast Augmentation segment is expected to be the largest during the forecast period
In the aesthetic market, the breast augmentation segment has the largest share. Breast augmentation is the surgical process of using implants or fat transfer to increase the size and shape of the breasts. The allure of breast augmentation is its capacity to alleviate cosmetic issues and enhance self-assurance. Moreover, the sustained popularity of this procedure in the aesthetic industry can be attributed to a number of factors, including evolving standards of beauty, a rise in body positivity, and improvements in surgical techniques.
The Clinics, Hospitals, And Medicals Spas segment is expected to have the highest CAGR during the forecast period
Throughout the forecast period, the medical spa segment is expected to have the highest CAGR. Medical spas provide a comprehensive approach to aesthetic care by combining the features of a traditional spa with medical services managed by certified healthcare professionals. Their appeal lies in offering cutting-edge aesthetic treatments along with relaxation and wellness services, giving customers a one-of-a-kind and all-inclusive experience. Furthermore, the medical spa model has the potential to have high growth because it frequently draws a diverse clientele looking for non-invasive procedures in a spa-like setting.
It is predicted that in the global aesthetic industry, North America will hold the largest share. Particularly in the United States, where there is a strong demand for a variety of aesthetic procedures, the market has grown significantly. A well-established healthcare system, a high degree of awareness regarding cosmetic procedures, and a strong emphasis on appearance and beauty are some of the factors that contribute to the region's prominence. Moreover, laser treatments, skin rejuvenation, body contouring, facial injectables, and other procedures are all part of the wide range of aesthetic procedures offered in North America.
With the highest CAGR, the Asia-Pacific region has become a dynamic force in the global aesthetic market. A growing middle class, changing beauty standards, and rising disposable incomes have all contributed to a boom in the demand for aesthetic procedures in nations like China, Japan, and South Korea. Additionally, the region has advanced to the forefront of the industry due to its quick uptake of non-invasive procedures and cultural acceptance of cosmetic enhancements.
Some of the key players in Medical Aesthetics market include Mentor Worldwide LLC, Lumenis, Bausch Health Companies Inc., Johnson & Johnson Services, Inc., Galderma Laboratories L.P, AbbVie Inc., Merz Pharmaceuticals GmbH, El.En. S.p.A. (Asclepion Laser Technologies), Syneron Medical, Ltd, Deka Laser Technologies, Solta Medical, Inc, Allergan plc, Sientra, Inc., Cynosure Inc., Sharplight Technologies Inc, Alma Lasers and Sciton Inc.
In June 2023, Bausch + Lomb Corporation, a subsidiary of Bausch Health Companies Inc., announced that it has entered into a definitive agreement with Novartis to acquire XIIDRA® 5%, a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye.
In March 2023, Galderma announced today the launch of FACE by Galderma™, an innovative aesthetic visualization tool powered by augmented reality (AR) that allows aesthetic professionals and patients to visualize injectable treatment results* at the planning stage before treatment begins. This innovative solution gives patients a simulated real-time "before and after" visual of what may be possible from an individualized treatment plan and may help alleviate patient concerns about injectable results.
In January 2023, Pharmaceutical companies AbbVie (ABBV.N) and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5% of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement.